127 related articles for article (PubMed ID: 21241384)
1. Use of biological molecules in the treatment of inflammatory bowel disease.
Nielsen OH; Seidelin JB; Munck LK; Rogler G
J Intern Med; 2011 Jul; 270(1):15-28. PubMed ID: 21241384
[TBL] [Abstract][Full Text] [Related]
2. Biological treatment of Crohn's disease.
Nielsen OH; Bjerrum JT; Seidelin JB; Nyberg C; Ainsworth M
Dig Dis; 2012; 30 Suppl 3():121-33. PubMed ID: 23295703
[TBL] [Abstract][Full Text] [Related]
3. [Must immunomodulators be added to biological treatment in inflammatory bowel disease?].
Gomollón F; Gisbert JP
Gastroenterol Hepatol; 2010 Jan; 33(1):43-53. PubMed ID: 19616870
[TBL] [Abstract][Full Text] [Related]
4. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
5. Use of biologic agents in pediatric inflammatory bowel disease.
Rosh JR
Curr Opin Pediatr; 2009 Oct; 21(5):646-50. PubMed ID: 19629010
[TBL] [Abstract][Full Text] [Related]
6. Safety issues with biological therapies for inflammatory bowel disease.
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752
[TBL] [Abstract][Full Text] [Related]
7. Emerging biological treatments in inflammatory bowel diseases.
Van Assche G; Vermeire S; Rutgeerts P
Dig Dis; 2006; 24(1-2):131-6. PubMed ID: 16699271
[TBL] [Abstract][Full Text] [Related]
8. Treatment with biologic therapies and the risk of cancer in patients with IBD.
Biancone L; Calabrese E; Petruzziello C; Pallone F
Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
[TBL] [Abstract][Full Text] [Related]
9. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
Orlando A; Mocciaro F; Civitavecchia G; Scimeca D; Cottone M
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S236-46. PubMed ID: 18598995
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease.
Ordás I; Feagan BG; Sandborn WJ
Clin Gastroenterol Hepatol; 2012 Oct; 10(10):1079-87; quiz e85-6. PubMed ID: 22813440
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy of inflammatory bowel diseases].
Wichan P; Chojnacki J; Wojtuń S
Pol Merkur Lekarski; 2004; 17 Suppl 1():40-3. PubMed ID: 15603345
[TBL] [Abstract][Full Text] [Related]
13. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.
Rahier JF; Buche S; Peyrin-Biroulet L; Bouhnik Y; Duclos B; Louis E; Papay P; Allez M; Cosnes J; Cortot A; Laharie D; Reimund JM; Lémann M; Delaporte E; Colombel JF;
Clin Gastroenterol Hepatol; 2010 Dec; 8(12):1048-55. PubMed ID: 20728573
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of chronic inflammatory bowel diseases].
Lémann M
Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
[TBL] [Abstract][Full Text] [Related]
15. Selecting appropriate anti-TNF agents in inflammatory bowel disease.
Yun L; Hanauer S
Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):235-48. PubMed ID: 19485806
[TBL] [Abstract][Full Text] [Related]
16. The state of the art in the management of inflammatory bowel disease.
Hanauer SB; Present DH
Rev Gastroenterol Disord; 2003; 3(2):81-92. PubMed ID: 12776005
[TBL] [Abstract][Full Text] [Related]
17. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
Ward MG; Irving PM; Sparrow MP
World J Gastroenterol; 2015 Oct; 21(40):11331-42. PubMed ID: 26525434
[TBL] [Abstract][Full Text] [Related]
18. Current dilemmas in the management of inflammatory bowel disease.
Rutgeerts P
Eur J Surg Suppl; 2002; (587):58-61. PubMed ID: 16144202
[TBL] [Abstract][Full Text] [Related]
19. Are patients with inflammatory bowel disease receiving optimal care?
Reddy SI; Friedman S; Telford JJ; Strate L; Ookubo R; Banks PA
Am J Gastroenterol; 2005 Jun; 100(6):1357-61. PubMed ID: 15929770
[TBL] [Abstract][Full Text] [Related]
20. Conventional medical management of inflammatory bowel disease.
Burger D; Travis S
Gastroenterology; 2011 May; 140(6):1827-1837.e2. PubMed ID: 21530749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
